JP2023525565A - Ｉｌ－２融合ポリペプチド組成物ならびにその作製及び使用方法 - Google Patents

Ｉｌ－２融合ポリペプチド組成物ならびにその作製及び使用方法 Download PDF

Info

Publication number
JP2023525565A
JP2023525565A JP2022568912A JP2022568912A JP2023525565A JP 2023525565 A JP2023525565 A JP 2023525565A JP 2022568912 A JP2022568912 A JP 2022568912A JP 2022568912 A JP2022568912 A JP 2022568912A JP 2023525565 A JP2023525565 A JP 2023525565A
Authority
JP
Japan
Prior art keywords
composition
polypeptide
certain embodiments
aqueous solution
nacl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022568912A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023525565A5 (enExample
Inventor
タレク・エー・ゼイダーン
マユール・カラリヤ
フランシスカ・オー・グボルミッタ
Original Assignee
アルカームス ファーマ アイルランド リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルカームス ファーマ アイルランド リミテッド filed Critical アルカームス ファーマ アイルランド リミテッド
Publication of JP2023525565A publication Critical patent/JP2023525565A/ja
Publication of JP2023525565A5 publication Critical patent/JP2023525565A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2022568912A 2020-05-11 2021-05-10 Ｉｌ－２融合ポリペプチド組成物ならびにその作製及び使用方法 Pending JP2023525565A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063022853P 2020-05-11 2020-05-11
US63/022,853 2020-05-11
PCT/US2021/031611 WO2021231316A1 (en) 2020-05-11 2021-05-10 Il-2 fusion polypeptide compositions and methods of making and using the same

Publications (2)

Publication Number Publication Date
JP2023525565A true JP2023525565A (ja) 2023-06-16
JP2023525565A5 JP2023525565A5 (enExample) 2024-05-22

Family

ID=78524918

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022568912A Pending JP2023525565A (ja) 2020-05-11 2021-05-10 Ｉｌ－２融合ポリペプチド組成物ならびにその作製及び使用方法

Country Status (12)

Country Link
US (1) US20210371486A1 (enExample)
EP (1) EP4149515A4 (enExample)
JP (1) JP2023525565A (enExample)
KR (1) KR20230009446A (enExample)
CN (1) CN115916242A (enExample)
AU (1) AU2021270745A1 (enExample)
BR (1) BR112022022764A2 (enExample)
CA (1) CA3172871A1 (enExample)
IL (1) IL298065A (enExample)
MX (1) MX2022014164A (enExample)
TW (1) TW202207970A (enExample)
WO (1) WO2021231316A1 (enExample)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63122628A (ja) * 1986-10-27 1988-05-26 シタス　コーポレイション 組換えインターフェロン−２の医薬組成物及び配合方法
JP2015525217A (ja) * 2012-06-08 2015-09-03 アルカーメス，インコーポレイテッド アゴニストおよびアンタゴニストとしての循環置換により修飾されるリガンド
JP2018500328A (ja) * 2014-12-19 2018-01-11 アルカーメス，インコーポレイテッド 一本鎖Ｆｃ融合タンパク質

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK11142002A3 (sk) * 1999-12-30 2004-09-08 Chiron Corporation Liečivo na podávanie interleukínu-2 a stabilizovaný lyofilizovaný alebo sprejovo sušený farmaceutický prostriedok s obsahom interleukínu-2
CN1816356A (zh) * 2003-05-14 2006-08-09 免疫原公司 药物缀合物组合物
JP2006137678A (ja) * 2004-11-10 2006-06-01 Shionogi & Co Ltd インターロイキン−２組成物
US10016415B2 (en) * 2014-08-18 2018-07-10 Alkermes Pharma Ireland Limited Aripiprazole prodrug compositions
WO2019019998A1 (zh) * 2017-07-25 2019-01-31 江苏恒瑞医药股份有限公司 一种il-15蛋白复合物药物组合物及其用途
US20210038684A1 (en) * 2019-06-11 2021-02-11 Alkermes Pharma Ireland Limited Compositions and Methods for Cancer Immunotherapy
BR112022007158A2 (pt) * 2019-10-18 2022-07-05 Alkermes Pharma Ireland Ltd Agentes imunomodulatórios de il-2 em combinação com inibidores do ponto de verificação imunológico
EP4093755A4 (en) * 2020-01-24 2024-07-31 Alkermes Pharma Ireland Limited PURIFICATION PROCESSES

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63122628A (ja) * 1986-10-27 1988-05-26 シタス　コーポレイション 組換えインターフェロン−２の医薬組成物及び配合方法
JP2015525217A (ja) * 2012-06-08 2015-09-03 アルカーメス，インコーポレイテッド アゴニストおよびアンタゴニストとしての循環置換により修飾されるリガンド
JP2018500328A (ja) * 2014-12-19 2018-01-11 アルカーメス，インコーポレイテッド 一本鎖Ｆｃ融合タンパク質

Also Published As

Publication number Publication date
KR20230009446A (ko) 2023-01-17
CA3172871A1 (en) 2021-11-18
CN115916242A (zh) 2023-04-04
EP4149515A4 (en) 2023-12-06
BR112022022764A2 (pt) 2023-01-17
IL298065A (en) 2023-01-01
MX2022014164A (es) 2023-02-22
TW202207970A (zh) 2022-03-01
AU2021270745A1 (en) 2022-12-15
WO2021231316A1 (en) 2021-11-18
US20210371486A1 (en) 2021-12-02
EP4149515A1 (en) 2023-03-22

Similar Documents

Publication Publication Date Title
RU2550271C2 (ru) Иммуногенная композиция для лечения или профилактики clostridium difficile, способ ее получения и способ индукции иммунного ответа к c. difficile
BRPI0403964B1 (pt) Formulações líquidas estáveis, artigo manufaturado e uso dessas formulações para o tratamento de disfunção mediada por ige
KR102720834B1 (ko) Il-15 단백질 복합체 약학 조성물 및 이의 용도
WO2015021861A1 (zh) 稳定的促胰岛素分泌肽水针药物组合物
JP2021178862A (ja) タンパク質製剤
JP2023506629A (ja) 安定した抗ｐｄ－１抗体の薬剤学的製剤
CN112516090B (zh) 抗体偶联药物的药物组合、冷冻干燥剂及制备方法、用途
TW200303756A (en) Lyophilised preparation comprising immunocytokines
KR20210113271A (ko) 콜라게나제 제형 및 이의 제조 방법
AU2020358101A1 (en) Anto-connexin antibody formulations
JPH0314520A (ja) インターロイキン―１組成物
EP3060256B1 (en) A novel stable formulation
Krieg et al. Overcoming challenges in co-formulation of proteins with contradicting stability profiles-EPO plus G-CSF
JP2023525565A (ja) Ｉｌ－２融合ポリペプチド組成物ならびにその作製及び使用方法
CN114504642A (zh) 一种含抗cldn18.2抗体的液体药物组合物
US20200299371A1 (en) Pharmaceutical composition comprising pegylated fab' fragment of anti-human ngf antibody
EP3236990A1 (en) Liquid pharmaceutical composition
CN116077646B (zh) 一种抗冠状病毒s蛋白的抗体制剂及其制备方法和用途
JP2023526024A (ja) Ｉｌ－２融合ポリペプチド組成物ならびにその作製及び使用方法
US20250302919A1 (en) Pharmaceutical compositions of efruxifermin
TW202308692A (zh) 包含帕博利珠單抗（ｐｅｍｂｒｏｌｉｚｕｍａｂ）的藥學組成物及其用途
EA045592B1 (ru) Жидкий препарат, содержащий антитело к il-17
CN117355321A (zh) 增强性能的赋形剂以及降低生物制剂的粘度和提高生物制剂的稳定性的方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240510

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240510

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250617

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251223